Aaron Larsen is an accomplished scientist with extensive experience in nucleic acid research and development. Currently serving as Chief Scientific Officer at Terrain Biosciences since April 2024, Aaron focuses on producing high-quality mRNA. Previously, Aaron held significant roles at Resilience, including Head of the Nucleic Acid Franchise, where leadership spanned scientific, regulatory, and technical operations related to various nucleic acid modalities. Prior to that, Aaron contributed to mRNA technology development at a startup and led teams at Beam Therapeutics and Moderna Therapeutics, specializing in CRISPR-based gene editing and mRNA therapeutics. With a strong academic foundation, Aaron earned a PhD in Chemistry from McGill University and pursued post-doctoral studies at Harvard University, complemented by a Mini-MBA from Harvard Business School.
This person is not in any teams
This person is not in any offices
Terrain Biosciences
At Terrain Bio, we help RNA therapeutics companies design and build better RNA, faster. Leveraging the latest innovations in protein and RNA design and the deep expertise of its scientific cofounders, we bring unparalleled speed and quality to RNA manufacturing.